Withaferin A decreases glycolytic reprogramming in breast cancer

Area of Science:

• Oncology
• Metabolic pathways
• Cancer research

Background:

• Reprogrammed glucose metabolism is a hallmark of cancer.
• Phytocompounds offer potential for inhibiting cancer metabolism.
• Withaferin A (WA) is a phytocompound derived from Withania somnifera.

Purpose of the Study:

• To investigate the ability of Withaferin A (WA) in modulating cancer metabolism.
• To assess the effect of WA on aerobic glycolysis in breast cancer cell lines.
• To validate in vitro findings in breast cancer patients.

Main Methods:

• Assessed the effect of WA on glucose uptake, lactate production, and ATP generation in breast cancer cell lines.
• Investigated the inhibition of key glycolytic enzymes (GLUT1, HK2, PKM2) and c-myc expression.
• Validated findings in approximately 2000 breast tumors by analyzing 90 metabolic pathways.

Main Results:

• WA decreases glucose uptake, lactate production, and ATP generation by inhibiting GLUT1, HK2, and PKM2.
• WA inhibits cancer glycolysis by targeting c-myc, leading to reduced cell viability, biomass, and colony formation.
• Glycolysis is the most deregulated pathway in breast tumors and predicts poor prognosis; c-myc expression correlates with glycolytic deregulation.

Conclusions:

• Withaferin A inhibits breast cancer metabolism via the c-myc/glycolysis axis.
• Targeting cancer metabolism with phytocompounds like WA presents a potential therapeutic strategy.
• Glycolytic deregulation and c-myc expression are significant prognostic indicators in breast cancer.